Circulating circRNA in Acute Ischemic Stroke

Acute Ischemic Stroke Clinical Trial

— CRAST  

Official title:

Clinical Significance of Circulating circRNA in Acute Ischemic Stroke (CRAST)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05098340
• Other study ID #: XYFY2021-KL107-01
• Status: Recruiting
• Start date: October 1, 2020
• Est. completion date: September 30, 2024

Study information

• Verified date: October 2021
• Source: The Affiliated Hospital of Xuzhou Medical University
• Contact: Xingzhi Wang, MD
• Phone: 0086-13852000759
• Email: wxz1220[@]126.com
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

CRAST is to analyze the expression pattern of circular RNA (circRNA) by bioinformatics analysis in patients with acute ischemic stroke and healthy control. The candidate circRNA will be verified as biomarkers for the detection and prognosis of acute ischemic stroke.

Description:

Circular RNAs have been highlighted to be involved in the pathological process of ischemic stroke (IS). The purpose of this protocol will investigate the expression pattern of circular RNA (circRNA) by bioinformatics analysis in patients with acute ischemic stroke and healthy control. The candidate circRNA will be verified as biomarkers for the detection and prognosis of acute ischemic stroke. Distinctive expression patterns of circRNA will be identified by individual quantitative real time polymerase chain reaction (qRT-PCR). A diagnostic or predictive model will be established using logistic regression. The panel of these altered circRNAs may be associated with acute IS and could serve as a novel diagnostic or predictive method.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 500
• Est. completion date: September 30, 2024
• Est. primary completion date: September 30, 2024
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Aged 18 years or older

• Confirmed acute ischemic stroke by a diffusion-weighted imaging-position lesion on magnetic resonance imaging (MRI) and a new lesion on a brain computed tomography (CT) scan

• Within 72 hours of symptom onset

• Good performance status

• Signed an approved informed consents

Exclusion Criteria:

• a history of hemorrhagic infarction, chronic kidney/liver diseases, peripheral arterial occlusive disease, active malignant disease, and inflammatory or infectious diseases

Related Conditions & MeSH terms

• Acute Ischemic Stroke
• Cerebral Infarction
• Ischemia
• Ischemic Stroke
• Stroke

Intervention

Genetic:
• Quantitative Real-time polymerase chain reaction
Quantitative Real-time polymerase chain reaction of circular RNA (circRNA).

Locations

Country	Name	City	State
China	Department of Neurology	Xuzhou	Jiangsu

Sponsors (1)

Lead Sponsor	Collaborator
The Affiliated Hospital of Xuzhou Medical University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Differential expression pattern of circRNA	Differential expression pattern of circular RNA (circRNA) will be compared between AIS group and HC group, thus candidate circRNA will be verified as biomarkers for the detection and prognosis of AIS.	90 days
Secondary	Dynamic changes of circRNA during the follow-up period	Dynamic changes of circRNA will be explored before and after endovascular therapy	90 days
Secondary	Correlation of circRNA and stroke-associated infection	Correlation of circRNA and stroke-associated infection will be explored in acute ischemic stroke.	30 days
Secondary	Correlation of circRNA and inflammatory factors in acute ischemic stroke	Correlation of circRNA and inflammatory factors on admission will be explored in acute ischemic stroke.	7 days
Secondary	Prognostic value of circRNA in acute ischemic stroke	The prognosis of AIS patients will be analyzed between differential expressed candidate circRNA after they have completed the systematic therapy.	90 days